OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced the advancement of two additional discovery programmes within its collaboration with Sanofi, with Exscientia receiving an aggregate of $15 million in milestone payments. Both lead compounds have met the product profile requirements, set by both Exscientia and Sanofi, to enable a transition to the lead optimisation phase within the collaboration.

英国牛津——（商业新闻短讯）——Exscientia plc（纳斯达克：EXAI）今天宣布，在与赛诺菲合作的范围内，将推进另外两个发现项目，Exscientia共收到1500万美元的里程碑付款。这两种先导化合物都符合Exscientia和赛诺菲制定的产品简介要求，以便在合作中过渡到先导优化阶段。

Both programmes have also shown a high level of differentiation in early profiling and have the potential to produce best-in-class assets..

这两个项目在早期分析中也显示出高度的差异性，并有可能产生一流的资产。。

“We are excited to announce the advancement of these programmes. This is testament to our consistent ability to design compounds that solve complex problems,” said David Hallett, Ph.D., interim Chief Executive Officer and Chief Scientific Officer of Exscientia. “We look forward to continuing to work with Sanofi to advance these programmes towards development, and ultimately working together to bring potential new treatment options to patients with significant unmet need.”.

Exscientia临时首席执行官兼首席科学官DavidHallett博士说：“我们很高兴宣布这些项目取得了进展。这证明了我们在设计解决复杂问题的化合物方面的一贯能力。”。“我们期待着继续与赛诺菲合作，推动这些计划的发展，并最终共同努力，为严重未满足需求的患者带来潜在的新治疗选择。”。

Exscientia will receive $15 million, in aggregate, for achieving these milestones. The payment is expected to be received by Exscientia in the fourth quarter of 2024 and reflected as cash inflows from collaborations and recognised as revenue over the duration of the collaboration. For these two programmes, Exscientia is also eligible to receive additional pre-commercial milestone payments of over $300 million and commercial milestones of over $300 million as well as tiered royalties on product sales ranging from high-single-digits to mid-teens, subject upon the achievement of certain specified research, development, regulatory and commercial milestones..

Exscientia将获得1500万美元，用于实现这些里程碑。预计Exscientia将于2024年第四季度收到这笔款项，并反映为合作产生的现金流入，并在合作期间确认为收入。对于这两个计划，Exscientia还可以获得额外的商业前里程碑付款超过3亿美元和商业里程碑超过3亿美元，以及产品销售的分层版税，从高个位数到十几岁，取决于某些特定的研究、开发、监管和商业里程碑的实现。。

About Exscientia

关于Exscientia

Exscientia is a technology-driven drug design and development company, committed to creating more effective medicines for patients, faster. Exscientia combines precision design with integrated experimentation, aiming to invent and develop the best possible drugs in the most efficient manner. Operating at the interfaces of human ingenuity, artificial intelligence (AI), automation and physical engineering, we pioneered the use of AI in drug discovery as the first company to progress AI-designed small molecules into a clinical setting.

Exscientia是一家技术驱动的药物设计和开发公司，致力于更快地为患者创造更有效的药物。。在人类创造力、人工智能（AI）、自动化和物理工程的界面上，我们率先将AI用于药物发现，成为第一家将人工智能设计的小分子应用于临床的公司。

We have developed an internal pipeline focused on oncology, while our partnered pipeline extends to many other therapeutic areas. By leading this new approach to drug creation, we believe we can change the underlying economics of drug discovery and rapidly advance the best scientific ideas into medicines for patients..

我们已经开发了一个专注于肿瘤学的内部管道，而我们的合作管道则扩展到许多其他治疗领域。通过领导这种药物创新的新方法，我们相信我们可以改变药物发现的潜在经济学，并迅速将最佳科学思想转化为患者的药物。。

For more information visit us on www.exscientia.com or follow us on LinkedIn @ex-scientia and X @exscientiaAI.

欲了解更多信息，请访问www.exscientia.com或通过LinkedIn@ex scientia和X@exscientiaAI关注我们。

Forward-looking Statements

前瞻性声明

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” and “projects” or similar expressions are intended to identify forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》中“安全港”条款含义内的某些前瞻性声明。。

All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the further development of the two programmes under the collaboration with Sanofi, including advancing the product candidates through optimisation phrase and into the clinic; the creation of best-in-class therapies which meet unmet medical needs in inflammation and oncology; expectations and benefits related to the Sanofi collaboration including the development of additional molecule programmes and potential for future milestone payments; and the ability of Exscientia’s technology to design compounds to create more effective medicines for patients.

除历史事实声明外，本新闻稿中的所有声明均为前瞻性声明。这些声明包括但不限于与赛诺菲合作进一步开发两个项目的声明，包括通过优化阶段推进候选产品并进入临床；创造一流的疗法，满足炎症和肿瘤学未满足的医疗需求；与赛诺菲合作相关的期望和收益，包括开发额外的分子计划和未来里程碑付款的潜力；以及Exscientia技术设计化合物为患者创造更有效药物的能力。

Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the initiation, scope and progress of Exscientia’s and its partners’ planned and ongoing preclinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the development and deployment of new technology and facilities; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics and the endeavour of building a business around such product candidates; and the process of creating a combined company with Recursion Pharmaceuticals and subsequent activities by any suc.

此类声明受到许多风险、不确定性和假设的影响，包括与Exscientia及其合作伙伴计划和正在进行的临床前研究和临床试验的启动、范围和进展以及由此产生的费用相关的风险、不确定性和假设；临床，科学，监管和技术发展；新技术和设施的开发和部署；发现、开发和商业化可用作人类治疗剂的安全有效候选产品的过程，以及围绕这些候选产品建立业务的努力；以及与Recursion Pharmaceuticals创建合并公司的过程以及任何suc的后续活动。